바이오 이미징 시장 : 제품별, 기술별, 모달리티별, 용도별, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Bio-imaging Market is projected to grow by USD 14.90 billion at a CAGR of 10.55% by 2032.

Bio-Imaging Market Introduction

The bio-imaging market is expanding as biomedical research, precision diagnostics, drug discovery, and image-guided care converge around higher-resolution visualization and quantitative image analytics. Demand is supported by the growing global burden of chronic disease; the International Agency for Research on Cancer reported about 20 million new cancer cases in 2022 and projects the total could rise to 35 million by 2050, reinforcing the need for earlier detection, treatment monitoring, and longitudinal imaging.

Across microscopy, MRI, CT, PET, SPECT, ultrasound, optical imaging, digital pathology, and molecular imaging, buyers are prioritizing systems that improve sensitivity, throughput, reproducibility, and workflow efficiency. Transformative Shifts in the Bio-Imaging Landscape

The bio-imaging landscape is shifting from standalone instruments to connected, software-defined imaging ecosystems. Laboratories and hospitals are increasingly seeking interoperable platforms that combine image capture, annotation, storage, analytics, and compliance-ready reporting, especially as multi-omics, spatial biology, and precision oncology require richer imaging context.

Funding and policy are also reshaping adoption. Horizon Europe's EUR 95.5 billion research program, the U.S. Cancer Moonshot, national precision medicine initiatives, and rising investment in digital pathology are accelerating translational imaging. At the same time, stricter data governance, cybersecurity, and medical device regulations are pushing vendors to build validated, auditable, privacy-preserving, and secure imaging workflows.

Cumulative Impact of Artificial Intelligence on Bio-Imaging

Artificial intelligence is becoming a cumulative force multiplier in bio-imaging by improving image reconstruction, denoising, segmentation, classification, registration, triage, and biomarker quantification. The U.S. FDA's public list of AI/ML-enabled medical devices surpassed 950 authorizations in 2024, with radiology representing the largest share, demonstrating how algorithmic imaging has moved from experimentation to regulated clinical use.

In research environments, AI supports high-content screening, cell phenotyping, tissue microenvironment analysis, digital pathology review, and automated microscopy quality control. The strongest opportunities will come from explainable AI models, curated and representative datasets, human-in-the-loop validation, and multimodal pipelines that integrate imaging with genomics, proteomics, electronic health records, and laboratory information systems.

Key Regional Insights for Bio-Imaging

Asia-Pacific is gaining momentum through China's scale in hospital infrastructure, Japan's advanced imaging installed base, India's expanding diagnostic access, Australia's translational research networks, and South Korea's high R&D intensity; OECD data consistently place South Korea among the world's highest research-and-development investors as a share of GDP. North America remains a leading commercialization hub because of strong NIH funding, FDA pathways for imaging software, advanced cancer centers, and early adoption of digital pathology, AI radiology, molecular imaging, and cloud-based medical imaging workflows.

Europe benefits from Horizon Europe, the European Health Data Space agenda, and strong academic-industry imaging clusters in Germany, France, the United Kingdom, Italy, and Spain, while EU medical device rules are increasing the importance of clinical evidence and post-market surveillance. Latin America is advancing through Brazil and Mexico's private diagnostics growth and oncology infrastructure needs, while the Middle East is supported by GCC hospital modernization programs, specialty care expansion, and national digital health strategies. Africa's opportunity is tied to portable ultrasound, tele-imaging, tuberculosis and infectious disease imaging, maternal health applications, and public-private capacity building to improve access in resource-constrained settings.

Key Group Insights Across Global Bio-Imaging Markets

ASEAN demand is rising as Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines invest in diagnostics capacity, biomedical research parks, medical tourism, and digital health infrastructure for large, underserved populations. The GCC is advancing premium imaging, oncology centers, AI-enabled hospital systems, and cloud-connected diagnostics through national transformation strategies, particularly in Saudi Arabia and the United Arab Emirates, where healthcare modernization is a core component of economic diversification.

The European Union provides scale through harmonized research funding, cross-border data policy, and strong biomedical networks, although MDR and IVDR compliance increases evidence expectations for imaging software and diagnostic workflows. BRICS countries broaden opportunity through large patient populations, expanding hospital capacity, scientific research output, and local manufacturing ambitions, while G7 markets remain innovation leaders in premium imaging, reimbursement sophistication, clinical validation, and academic translation. NATO countries add defense-health relevance through trauma imaging, field diagnostics, medical readiness, and resilient medical supply chains that support both civilian and emergency-care bio-imaging applications.

Key Country Insights in Bio-Imaging

The United States leads in biomedical imaging innovation due to large academic medical centers, NIH-backed research, venture funding, advanced radiology and pathology networks, and a mature FDA framework for imaging devices and AI-enabled software. Canada contributes strengths in AI research, population health imaging, and publicly funded care pathways; Mexico benefits from nearshoring, private diagnostics, and cross-border healthcare activity; and Brazil is Latin America's largest healthcare market, with rising oncology, cardiology, and imaging demand supported by a large hospital base.

In Europe, the United Kingdom, Germany, France, Italy, Spain, and Russia each support demand through hospital modernization, research institutions, and national screening needs, with Germany standing out for engineering, medtech manufacturing, and advanced imaging adoption. The United Kingdom has strengths in genomics-linked imaging research and NHS digital transformation, France supports oncology and nuclear medicine capabilities, Italy and Spain are improving diagnostic capacity across public and private networks, and Russia maintains demand through large tertiary-care systems. In Asia-Pacific, China and India provide scale through expanding healthcare access and chronic disease needs, Japan and South Korea deliver advanced technology adoption and aging-population imaging demand, and Australia contributes high-quality clinical research, cancer imaging networks, population screening programs, and digital health readiness.

Actionable Recommendations for Bio-Imaging Industry Leaders

Industry leaders should prioritize interoperable imaging platforms that connect instruments, laboratory information systems, PACS, cloud repositories, digital pathology systems, and AI analytics. Product roadmaps should emphasize validated software, regulatory documentation, cybersecurity, data provenance, auditability, and compatibility with DICOM, HL7, FHIR, and microscopy metadata standards.

Commercial teams should align offerings with regional evidence requirements, clinical workflows, and buyer economics. In mature markets, differentiation should focus on automation, AI performance, reproducibility, image quality, workflow integration, and total cost of ownership. In emerging markets, portable systems, training, remote support, leasing models, ruggedized equipment, and public-private partnerships can unlock adoption while improving access to biomedical imaging.

Research Methodology

This executive summary is grounded in secondary research from verified public and institutional sources, including regulatory databases, national research funding programs, cancer statistics, peer-reviewed biomedical imaging literature, clinical imaging guidelines, and publicly available policy documents. Sources assessed include agencies such as the FDA, NIH, IARC, WHO, OECD, European Commission, and national health authorities.

The analysis applies a structured market intelligence approach, combining demand-side healthcare indicators, technology adoption signals, regulatory developments, procurement trends, research funding patterns, and regional macroeconomic context. Insights were triangulated across clinical imaging, life science imaging, digital pathology, high-content screening, molecular imaging, preclinical imaging, and AI image analysis to identify durable bio-imaging market drivers without relying on market size, share, or forecast assumptions.

Conclusion

Bio-imaging is becoming a foundational layer of precision medicine, translational research, clinical diagnostics, and pharmaceutical innovation. The market is being shaped by higher disease burden, demand for earlier diagnosis, spatial biology, digital pathology, cloud-connected workflows, and the rapid integration of artificial intelligence into imaging pipelines.

Sustained progress will depend on trust, validation, interoperability, cybersecurity, and measurable workflow value. Organizations that combine high-quality imaging hardware with compliant software, AI-ready data infrastructure, robust clinical evidence, and region-specific commercialization strategies will be best positioned to lead the next phase of the global bio-imaging market.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Bio-imaging Market, by Product

• 7.1. Imaging Systems
• 7.2. Instruments
  • 7.2.1. CT Scanners
  • 7.2.2. MRI Machines
  • 7.2.3. Ultrasound Devices
• 7.3. Reagents
• 7.4. Software
  • 7.4.1. Data Management Software
  • 7.4.2. Image Analysis Software

8. Bio-imaging Market, by Technology

• 8.1. Endoscopy
• 8.2. Magnetic Resonance Imaging
• 8.3. Nuclear Imaging
• 8.4. Surgical Microscopy
• 8.5. Ultrasound
• 8.6. X-ray Imaging

9. Bio-imaging Market, by Modality

• 9.1. 2D Imaging
• 9.2. 3D Imaging

10. Bio-imaging Market, by Application

• 10.1. Clinical Diagnostics
• 10.2. Drug Discovery
• 10.3. Research
• 10.4. Therapeutics

11. Bio-imaging Market, by End User

• 11.1. Ambulatory Surgical Centers
• 11.2. Diagnostic Imaging Centers
• 11.3. Hospitals & Clinics

12. Bio-imaging Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Bio-imaging Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Bio-imaging Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. BaySpec, Inc.
• 16.2. Bracco S.p.A.
• 16.3. Bruker Corporation
• 16.4. Canon Medical Systems Corporation
• 16.5. Digirad Corporation
• 16.6. Esaote S.p.A
• 16.7. Fujifilm Holdings Corporation
• 16.8. GE HealthCare Technologies, Inc.
• 16.9. Hitachi Medical Corporation
• 16.10. HT BioImaging Ltd
• 16.11. iThera Medical GmbH
• 16.12. Kitware, Inc.
• 16.13. Koninklijke Philips N.V.
• 16.14. Lantheus Medical Imaging, Inc.
• 16.15. M Squared Lasers Ltd.
• 16.16. MARS Bioimaging Limited
• 16.17. Medtronic PLC
• 16.18. MobileODT Ltd by Liger Medical LLC
• 16.19. Perspectum Ltd.
• 16.20. Quibim, S.L.
• 16.21. RadNet, Inc.
• 16.22. Rivanna Medical, Inc.
• 16.23. Samsung Medison Co., Ltd.
• 16.24. Siemens Healthineers AG